CL2019002629A1 - Análogos de deutetrabenazina, su preparación y uso. - Google Patents

Análogos de deutetrabenazina, su preparación y uso.

Info

Publication number
CL2019002629A1
CL2019002629A1 CL2019002629A CL2019002629A CL2019002629A1 CL 2019002629 A1 CL2019002629 A1 CL 2019002629A1 CL 2019002629 A CL2019002629 A CL 2019002629A CL 2019002629 A CL2019002629 A CL 2019002629A CL 2019002629 A1 CL2019002629 A1 CL 2019002629A1
Authority
CL
Chile
Prior art keywords
deutetrabenazine
analogs
preparation
compositions
same
Prior art date
Application number
CL2019002629A
Other languages
English (en)
Spanish (es)
Inventor
Chengzi Zhang
Jim Kerr
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of CL2019002629A1 publication Critical patent/CL2019002629A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Machine Translation (AREA)
  • Pens And Brushes (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CL2019002629A 2017-03-15 2019-09-13 Análogos de deutetrabenazina, su preparación y uso. CL2019002629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15

Publications (1)

Publication Number Publication Date
CL2019002629A1 true CL2019002629A1 (es) 2020-01-24

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002629A CL2019002629A1 (es) 2017-03-15 2019-09-13 Análogos de deutetrabenazina, su preparación y uso.

Country Status (20)

Country Link
US (4) US11813232B2 (enExample)
EP (1) EP3596077A1 (enExample)
JP (3) JP7608050B2 (enExample)
KR (2) KR20200003791A (enExample)
CN (1) CN110709398A (enExample)
AR (1) AR111182A1 (enExample)
AU (2) AU2018236336B2 (enExample)
BR (1) BR112019018966A2 (enExample)
CA (1) CA3056612A1 (enExample)
CL (1) CL2019002629A1 (enExample)
CO (1) CO2019011271A2 (enExample)
EA (1) EA201992168A1 (enExample)
IL (1) IL269132A (enExample)
MX (1) MX2019010913A (enExample)
PE (1) PE20191819A1 (enExample)
SG (1) SG11201908477QA (enExample)
TW (1) TWI772382B (enExample)
UA (1) UA127052C2 (enExample)
WO (1) WO2018170214A1 (enExample)
ZA (1) ZA201906326B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813232B2 (en) 2017-03-15 2023-11-14 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use
WO2020123900A1 (en) 2018-12-13 2020-06-18 Auspex Pharmaceuticals, Inc. Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
EP4153136B1 (en) * 2020-06-10 2024-01-10 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
CA2736409C (en) * 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2883641C (en) * 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
US11813232B2 (en) 2017-03-15 2023-11-14 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use

Also Published As

Publication number Publication date
AU2018236336B2 (en) 2022-02-24
NZ757789A (en) 2024-08-30
US11179386B2 (en) 2021-11-23
AR111182A1 (es) 2019-06-12
KR20200003791A (ko) 2020-01-10
CA3056612A1 (en) 2018-09-20
US11813232B2 (en) 2023-11-14
EA201992168A1 (ru) 2020-03-16
AU2022203369B2 (en) 2024-04-04
US20180263972A1 (en) 2018-09-20
EP3596077A1 (en) 2020-01-22
CN110709398A (zh) 2020-01-17
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
KR20230003308A (ko) 2023-01-05
TWI772382B (zh) 2022-08-01
MX2019010913A (es) 2020-01-20
US12502385B2 (en) 2025-12-23
PE20191819A1 (es) 2019-12-27
ZA201906326B (en) 2022-12-21
CO2019011271A2 (es) 2020-02-28
AU2022203369A1 (en) 2022-06-09
US20220040170A1 (en) 2022-02-10
JP2024050724A (ja) 2024-04-10
US20220088006A1 (en) 2022-03-24
UA127052C2 (uk) 2023-03-29
US20200016148A1 (en) 2020-01-16
TW201840317A (zh) 2018-11-16
JP2020510073A (ja) 2020-04-02
JP7631572B2 (ja) 2025-02-18
JP7608050B2 (ja) 2025-01-06
JP2023010754A (ja) 2023-01-20
IL269132A (en) 2019-11-28
BR112019018966A2 (pt) 2020-04-22
WO2018170214A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
DOP2017000298A (es) Reguladores de nrf2
CL2020001271A1 (es) Inhibidores de kras g12c
DOP2018000175A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
CO2019011271A2 (es) Análogos de deutetrabenazina, su preparación y uso
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
MX2021006977A (es) Anellosomas y metodos de uso.
DOP2016000145A (es) Reguladores de nrf2
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
UY37410A (es) Antagonistas de trpv4
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2016011176A (es) Polipeptidos fhbp meningococicos modificados.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
PY18111999A (es) Hidroxiisoxazolinas y derivados de estos
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
CL2022001612A1 (es) Tieniloxazolonas y análogos
MX2017000862A (es) Formulacion de factor viii.
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
AR108616A1 (es) Formulación combinada de tres compuestos antivirales